Aprocitentan
Payments companies reported to CMS as associated with Aprocitentan. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Aprocitentan, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Aprocitentan
These are the largest totals companies reported as associated with Aprocitentan. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Florian Rader | West Hollywood, CA | Cardiovascular Disease | $16,523.77 |
| Michael Weber | West Islip, NY | $12,860.97 | |
| James Byrd | Ann Arbor, MI | Cardiovascular Disease | $11,059.70 |
| Vivek Bhalla | Stanford, CA | Nephrology (Internal Medicine) | $10,277.43 |
| Michael Bloch | Reno, NV | Internal Medicine | $8,987.21 |
| Luke Laffin | Chicago, IL | Internal Medicine | $8,983.23 |
| Debbie Cohen Stein | Philadelphia, PA | Nephrology (Internal Medicine) | $6,221.47 |
| Ajay Kirtane | New York, NY | Interventional Cardiology | $2,460.18 |
Prescribed Aprocitentan?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.